The IMMUNOBIOGRAM® is an In Vitro Diagnostic immunoassay that combines a biotechnological KIT and a software for data interpretation.
The IMMUNOBIOGRAM® is a tool that helps physicians to adapt the immunosuppressive therapy in patients with a kidney transplant, allowing them to select for each patient the most adequate combination of immunosuppressive drugs (IMS) and doses, to avoid kidney rejection and reduce the side effects of treatments.
The IMMUNOBIOGRAM® is performed with a 3D-cell culture of peripheral blood mononuclear cells (PBMCs) subdued to a specific immune stimulation which replicates the physiological immune response of each patient. The PBMCs are included in a hydrogel and exposed to each IMSs in different channels. The hydrogel is capable of a spontaneous generation of IMSs concentration-gradient due to a passive-diffusion process. An indicator of cell-proliferation/viability reveals the capacity of the IMSs-gradient to inhibit the patient´s immune activation cells state.
Cellular pharmacodynamics of immunosuppressive drugs is an efficient strategy to predict the clinical efficacy of drugs in many immunological disorders and organ transplantations (Hirano T 2007, Francis DM 1988). A concomitant evaluation of pharmacodynamics/ pharmacokinetics of the drugs would be useful to perform successful patient-tailored immunosuppressive therapy.
This endpoint immunoassay offers a personalized comparative evaluation of a patient´s sensitivity/resistance profile to a panel of the most commonly prescribed IMSs, allowing to predict and monitor the patients ‘response to IMSs.
